One active comparator, in one trial, is the whole of it

Published 24 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
The only published direct comparison is the Lancet 2023 phase 2 trial in type 2 diabetes, which included dulaglutide at a standard clinical dose alongside placebo. Higher retatrutide groups exceeded it on glycated haemoglobin and on weight over 36 weeks. No published trial compares retatrutide with semaglutide or tirzepatide.

The comparison that exists

Rosenstock and colleagues randomised 281 adults with type 2 diabetes to placebo, to dulaglutide, or to one of several retatrutide groups. Dulaglutide is an approved long-acting GLP-1 receptor agonist from the same sponsor. At 24 and 36 weeks the higher retatrutide groups showed greater reductions in glycated haemoglobin and in weight than the comparator.

This is evidence about retatrutide relative to dulaglutide at that dose in that population over that period.

What it does not cover

Dulaglutide is not the most potent GLP-1 receptor agonist available, and it is a single-receptor agent. The comparison does not place retatrutide against semaglutide or against the dual agonist tirzepatide, which are the comparisons most often asked about.

Nor does a 36-week phase 2 comparison speak to durability or to rare adverse events.

Where further comparisons would come from

Phase 3 programmes sometimes include active comparator arms, and independent head-to-head trials are sometimes run after approval. Trial registrations are public and show what comparators, if any, have been designed in. Until a paper is published, this site reports none.

Retatrutide is supplied by REVIVE LAB UAE as an investigational research material for laboratory use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not approved for any use anywhere, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
Retatrutide Pack20 mgAED 1010In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

The comparison that exists?

Rosenstock and colleagues randomised 281 adults with type 2 diabetes to placebo, to dulaglutide, or to one of several retatrutide groups. Dulaglutide is an approved long-acting GLP-1 receptor agonist from the same sponsor. At 24 and 36 weeks the higher retatrutide groups showed greater reductions in glycated haemoglobin and in weight than the comparator.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

Retatrutide Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.